← 홈

혈액암 (AML/ALL) · VEGF

23개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-13 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 23개
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

China-approved Bevacizumab (China-approved Bevacizumab)

Metastatic Colorectal Cancer (CRC) · Advanced Non-squamous Non-small-cell Lun

#AdvancedNon-squamousNon-small-ce#Antibody#Phase3#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleRochePhase 2

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleImmunityBio, Inc.Phase 3

atezolizumab (Tecentriq, Carboplatin and paclitaxel plus atezolizumab and bevacizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 40.3%임상시험 1상태 ACTIVE
CGTBiologicstaleRochePhase 2

NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy (NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

1 / 2 페이지

← 이전다음 →